Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Grape King BioTPE:1707 +0.68%78 Debt-to-EBITDA is 0.10 as of Mar. 2026, which is 58% below its 10-year median of 0.24. GuruFocus rates TPE:1707 with a GF Score™ of 78/100 and a GF Value™ of NT$138.87 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 681 Drug Manufacturers companies, Grape King Bio ranks better than 89.57% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Grape King Bio's Debt-to-EBITDA or its related term are showing as below:
TPE:1707'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.05 Med: 0.24 Max: 0.74
Current: 0.07
During the past 13 years, the highest Debt-to-EBITDA Ratio of Grape King Bio was 0.74. The lowest was 0.05. And the median was 0.24.
TPE:1707's Debt-to-EBITDA is ranked better than 89.57% of 681
companies
in the Drug Manufacturers industry
Industry Median: 1.62
vs TPE:1707: 0.07
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Grape King Bio Debt-to-EBITDA Related Terms
Grape King Bio Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Grape King Bio's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Grape King Bio's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grape King Bio Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grape King Bio's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Grape King Bio's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Grape King Bio (TPE:1707) has a Debt-to-EBITDA of 0.10 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Grape King Bio. This is 58% below median its historical median of 0.24. Over the past decade, Grape King Bio's Debt-to-EBITDA has ranged from 0.05 to 0.74. According to the industry distribution chart, Grape King Bio ranks #71 out of 681 companies in the Drug Manufacturers industry, placing it in the top 10.4%.
Is Grape King Bio's Debt-to-EBITDA too high?
Grape King Bio's current Debt-to-EBITDA of 0.10 is 58% below median its 10-year median of 0.24. Over the past 10 years, this metric has ranged from a low of 0.05 to a high of 0.74. The Drug Manufacturers industry median Debt-to-EBITDA is 1.62. Grape King Bio's value of 0.10 is 93.8% below this industry median. Based on the distribution chart, Grape King Bio ranks #71 out of 681 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Grape King Bio has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Grape King Bio's Debt-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Grape King Bio ranks #71 out of 681 companies for Debt-to-EBITDA. This places Grape King Bio in the top 10% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.62. Grape King Bio's value of 0.10 is 93.8% below this benchmark. Historically, Grape King Bio's own Debt-to-EBITDA has ranged from 0.05 to 0.74 over the past decade. While the company's 10-year median is 0.24 vs. the industry median of 1.62, Grape King Bio has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.62, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grape King Bio's current Debt-to-EBITDA of 0.10 is 93.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Grape King Bio. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grape King Bio's current Debt-to-EBITDA is 0.10, which is 58% below median its own 10-year median of 0.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grape King Bio stock overvalued right now?
Based on GuruFocus' analysis, Grape King Bio (TPE:1707) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$138.87, compared to a current price of NT$89.30 — trading 35.7% below its estimated fair value. The current Debt-to-EBITDA is 0.10, which is 58% below median its 10-year median of 0.24 and 93.8% below the Drug Manufacturers industry median of 1.62. Grape King Bio's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Grape King Bio (TPE:1707), the current Debt-to-EBITDA is 0.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grape King Bio (TPE:1707) Overvalued in 2026?
Based on GuruFocus' analysis, Grape King Bio stock appears to be undervalued.
The current stock price of NT$89.30 is trading 35.7% below its estimated GF Value™ of NT$138.87.
GuruFocus considers Grape King Bio to be Significantly Undervalued.
Key valuation signals for TPE:1707:
Debt-to-EBITDA: 0.10 (58% below median its 10-year median of 0.24)
GF Value™: NT$138.87 vs. price of NT$89.30 (35.7% below fair value)
Industry Position: 93.8% below the Drug Manufacturers median (#71 of 681)
No single metric tells the full story. See the TPE:1707 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grape King Bio Ltd is a specialty and generic drug manufacturing company engaged in producing and selling pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy food. The company has three segments: MLM (Multi-Level Marketing), which is a direct seller of Pro-partner Inc, including the company's development and manufacturing products for Pro-partner Inc, the Distributors segment includes the company's self-owned brand products, and ODM/OEM (Original Design Manufacturer/Original Equipment Manufacturer) includes ODM/OEM in Taiwan and Shanghai. The group operates in three principal geographical areas - Taiwan, China, and Others, and it derives a majority of its revenue from Taiwan.
78GF Score
Get the complete analysis for TPE:1707
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1707 has been successfully added to your 
